Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Jan 27, 2021
Open Peer Review Period: Jan 27, 2021 - Mar 24, 2021
Date Accepted: Apr 15, 2021
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study

Chen CS, Kim J, Guntupalli H, Garg N, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, Hertz DL

Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study

JMIR Mhealth Uhealth 2021;9(7):e27502

DOI: 10.2196/27502

PMID: 36260403

PMCID: 8406129

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Chemotherapy-induced peripheral neuropathy detection via smartphone app in a cross-sectional pilot study

  • Ciao-Sin Chen; 
  • Judy Kim; 
  • Harsha Guntupalli; 
  • Noemi Garg; 
  • Reshma Jagsi; 
  • Jennifer J Griggs; 
  • Michael Sabel; 
  • Michael P Dorsch; 
  • Brian Callaghan; 
  • Daniel L Hertz

ABSTRACT

Background:

Severe chemotherapy-induced peripheral neuropathy (CIPN) can cause long-term dysfunction of the hands and feet, interfere with activities of daily living, and diminish quality of life. Monitoring to identify CIPN before it progresses to life-altering severity relies on patients self-reporting subjective symptoms to their clinical team. Objective assessment is not a standard component of CIPN monitoring due to the requirement for specially trained healthcare professionals and equipment. Smartphone apps have the potential to conveniently collect both subjective and objective CIPN data directly from patients, which could improve CIPN monitoring.

Objective:

The objective of this cross-sectional pilot study was to assess the feasibility of functional CIPN assessment via smartphone app.

Methods:

Twenty-six patients who had completed neurotoxic chemotherapy were enrolled and classified as CIPN cases (n=16) or controls (n=10) based on self-report symptoms. All participants completed CIPN assessments within the NeuroDetect app a single time including patient-reported surveys (CIPN20 and PRO-CTCAE) and functional assessments (Gait and Balance and 9 Hole Peg Test).

Results:

Exploratory comparisons between CIPN cases and controls indicate CIPN cases had shorter step length (P=.003), unique swaying acceleration patterns during a walking task, and shorter hand moving distance during a manual dexterity task.

Conclusions:

Our results confirm that remote CIPN assessment via a smartphone app is feasible and suggest that functional data may be indicative of CIPN manifestations in the hands and feet. Additional work is needed to determine which functional assessments are most indicative of CIPN and could be used for CIPN monitoring within clinical care.


 Citation

Please cite as:

Chen CS, Kim J, Guntupalli H, Garg N, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, Hertz DL

Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study

JMIR Mhealth Uhealth 2021;9(7):e27502

DOI: 10.2196/27502

PMID: 36260403

PMCID: 8406129

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.